Head-to-head evidence
DA-302168S vs orforglipron
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
DA-302168S
Developed by Chendu DIAO Pharmaceutical Group
NCT06953063 · Phase 2 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 250 participants, with percentage change in body weight as a clinical primary endpoint. However, results are not posted, so it is not possible to determine whether the primary comparison was met; the available evidence therefore supports a moderate grade rather than a strong one.
Next expected readout: July 2027 · NCT07629544 (registry estimate)
orforglipron · Foundayo
Marketed by Eli Lilly
NCT05803421 · Phase 3 · completed
The study is randomized and active-controlled with a large sample of 2,749 participants, but it is open-label rather than blinded. Its primary endpoint is a hard clinical cardiovascular outcome; however, the comparison cannot be judged because no results are currently available.
Next expected readout: February 2027 · NCT06672549 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DA-302168S's landscape · orforglipron's landscape